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Purpose: The purpose of this study was to validate the dosimetric performance of
scanned ion beam deliveries with motion-synchronization to heterogenous targets.
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Methods: A 4D library of treatment plans, comprised of up to 10 3D sub-plans, was
created with robust and conventional 4D optimization methods. Each sub-plan
corresponded to one phase of periodic target motion. The plan libraries were delivered
to a test phantom, comprising plastic slabs, dosimeters, and heterogenous phantoms.
This phantom emulated range changes that occur when treating moving tumors. Similar
treatment plans, but without motion synchronization, were also delivered to a test
phantom with a stationary target and to a moving target; these were used to assess
how the target motion degrades the quality of dose distributions and the extent to which
motion synchronization can improve dosimetric quality. The accuracy of calculated dose
distributions was veriﬁed by comparison with corresponding measurements.
Comparisons utilized the gamma index analysis method. Plan quality was assessed
based on conformity, dose coverage, overdose, and homogeneity values, each extracted
from calculated dose distributions.
Results: High pass rates for the gamma index analysis conﬁrmed that the methods used
to calculate and reconstruct dose distributions were sufﬁciently accurate for the purposes
of this study. Calculated and reconstructed dose distributions revealed that the motionsynchronized and static deliveries exhibited similar quality in terms of dose coverage,
overdose, and homogeneity for all deliveries considered. Motion-synchronization
substantially improved conformity in deliveries with moving targets. Importantly,
measurements at multiple locations within the target also conﬁrmed that the motionsynchronized delivery system satisfactorily compensated for changes in beam range
caused by the phantom motion. Speciﬁcally, the overall planning and delivery approach
achieved the desired dose distribution by avoiding range undershoots and overshoots
caused by tumor motion.
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Conclusions: We validated a dose delivery system that synchronizes the movement of
the ion beam to that of a moving target in a test phantom. Measured and calculated dose
distributions revealed that this system satisfactorily compensated for target motion in the
presence of beam range changes due to target motion. The implication of this ﬁnding is
that the prototype system is suitable for additional preclinical research studies, such as
irregular anatomic motion.
Keywords: motion-synchronized dose delivery, carbon ion therapy, range compensation, motion mitigation, multiphase 4D delivery, scanned ion beams

complexity of motion mitigation, but increases the compliance
requirements of patients, and some patients cannot comply with
respiratory requirements. The most technologically advanced
approach, commonly called 4D-optimized tracking, allows the
patient to breath freely and requires the treatment system to
modify the trajectories of the delivered ion beams to follow the
moving tumor, using real-time monitoring of the tumor
position. This approach, developed at GSI for more than a
decade (12), revealed promising dosimetric qualities and
technical feasibility, but the vast technological complexity
required to compensate anatomical motion has thus far been a
major obstacle to its translation to clinical practice. To overcome
these obstacles, Lis et al. (13) developed a technologically
straightforward approach, called multi-phase 4D beam delivery
(MP4D), which provides comparable dosimetric quality to that
of beam tracking without the associated complications. It takes
anatomical and tumor motion into account during treatment
planning and subsequently synchronizes the beam delivery in
real-time so that it follows the moving tumor. The MP4D
approach was previously characterized for moving targets with
promising preliminary results, but the tests did not attempt to
compensate for range changes that occur in a heterogeneous
phantom. To our knowledge, no system with such capabilities
has yet been validated or clinically commissioned.
The objective of this study was to validate, by measurement
and calculation, the performance of a recently created motionsynchronized dose delivery system (M-DDS) (13), used to deliver
MP4D treatments. In particular, we validated, for the ﬁrst time,
the ability of the M-DDS to compensate for tumor motion in the
presence of anatomical, motion-induced range changes. Libraries
of 4D-optimized carbon-ion treatment plans were delivered to
phantoms and absorbed dose distributions were measured. The
dosimetric quality was assessed by examination of the dose
coverage, conformity, overdose and uniformity. These
quantities were compared for deliveries with a variety of test
cases, including those with stationary and moving tumors, with
and without the application of motion synchronization.

INTRODUCTION
Proton and ion therapy provide conformal dose distributions for
static targets, and in the past few decades, have emerged as a
formidable alternative to photon therapy. Ion therapies have
mainly been used to treat static tumors, including several in the
regions of the head and neck region, cranium, retina, and the
spine, with high conformity (1, 2), resulting in reduced toxicities
and tumor recurrence (3). Conformal treatments have been
shown to be partially effective in reducing complications
associated with radiotherapy of moving tumors, such as nonsmall cell lung cancer, including pneumonitis and cardiac
complications (4, 5). However, contemporary ion beam
therapies for thoracic tumors still have high complication rates
and low survival rates (6). Additional unmet clinical needs
include shorter treatment times and streamlined patientspeciﬁc quality assurance procedures. Thus, it is imperative to
develop treatment methods that can meet these clinical needs.
Currently, about two thirds of proton and ion therapy centers
use relatively simple motion mitigation strategies to treat moving
tumors, including various combinations of techniques such as
breath hold, beam gating, and internal target volumes (ITV),
used with or without rescanning (7). These motion mitigation
strategies for scanned ion therapy have been used to successfully
treat some, but not all, moving tumors, yet treatment
complication rates remain a serious problem (8, 9). The local
failures are largely believed to be caused by insufﬁcient dose to
the tumor and complications are believed to be caused by
excessive dose to surrounding healthy tissues (10). An obvious
approach to overcome these limitations is to amend treatment
planning and dose delivery methods to increase tumor coverage
and reduce dose to normal tissues. To achieve these,
improvements are needed to mitigate against range variations
that are induced by moving heterogenous anatomy, including
cases where the movements of the tumor and surrounding
healthy tissue differ from one another. The most advanced
motion mitigation approach currently in clinical use, namely
the phase-controlled rescanning method at the National Institute
of Radiological Sciences (NIRS), combines rapid beam delivery
with ﬂuoroscopy-guided beam gating. This requires minimal
changes to the target position during the time where the
treatment unit actively delivers beam to the tumor. With this
approach, treatments must be halted if tumor motion changes
substantially from the expected tumor location (11). The
advantage of the gating approach is that it avoids the technical
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MATERIALS AND METHODS
We validated a prototype system to treat moving targets with
scanned ion beams. The overall approach was to synchronize the
delivery of the beam to the periodic motion of the target, to allow
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were created for both target volumes, on all 4DCT images and to
a homogeneous absorbed dose of 3 Gy.
The plan libraries were delivered with the motionsynchronized dose delivery system (M-DDS) (13), which was
created to accelerate research and translation of motion
mitigation strategies in ion therapy. This system was
implemented in a research version of the dose delivery system
(DDS) that is used clinically at the National Center for
Oncological Hadrontherapy (CNAO) (20). It was similarly
implemented in the radiotherapy research facility (Cave M) at
GSI (21).
The general approach considers motion of the entire anatomy
during treatment planning. This allows for compensating for the
motion of heterogeneous tissue and variable target depths
without the need for real-time modiﬁcations to the beam spot
delivery positions during delivery. Instead, the real-time target
position is monitored to redirect delivery from sub-plan to subplan, as the target moves to another motion phase. As such, the
sub-plans are delivered as a series of discrete stationary plans.
This continues until the entire prescription dose is delivered. For
this study, up to 10 motion phases were considered,
corresponding to the number of phases typically found in a
4DCT for lung cancer patients; however, additional motion
phases can be trivially added if needed. Though the number of
motion phases is discrete, the tumor motion is continuously
monitored, and a variety of motion monitoring devices can
be selected.
In this study, we used continuous monitoring of target
motion to adapt the delivery sequence of sub-plans. The 1D
target motion was monitored with an optical distance sensor
(OD100—35P840, SICK, Waldkirch, Germany). The signal
amplitude was digitized and analyzed to yield a discrete
motion phase. The sub-plan found in the plan library,
corresponding to the detected phase, was then accessed.
During beam delivery, the beam spots in the sub-plan that
corresponded to the detected motion phase were delivered in
sequence until complete, or until another motion phase was
detected. When another phase was detected, the delivery was
then redirected to the nearest beam spot within the
corresponding sub-plan and delivery continued as before. Once
all of the spots in an iso-energy slice (IES) were delivered for the
given sub-plan, the beam was suspended until delivery was
directed to a sub-plan containing yet undelivered spots of the
same energy. This process continued until all beam spots for that
IES were delivered, then delivery progressed to the next IES. For
deliveries to static targets (plan libraries with one motion phase),
all the beam spots are delivered in sequence for each IES until all
beam spots were delivered.
At the time of this study, the refurbished accelerator system at
GSI was only capable of single-energy deliveries and the beam
range was modulated with a range shifter to deliver beams to
entire target volumes. Subsequent work will implement fast and
automated switching between accelerated beam energies to
efﬁciently deliver multiple beam energies. Therefore, all plans
were delivered with a nominal beam energy of 280 MeV/u. As a
provisional means to produce multiple beam energies and ranges

for almost continuous delivery of the beam to the moving target.
This approach inherently includes compensating for motion in
heterogenous anatomy, which would otherwise cause range overand under-shoots due to the anatomical, motion-induced range
changes. For the convenience of the reader, we brieﬂy review
here the previously reported methods for motion mitigation with
MP4D deliveries (13, 14), the treatment planning system (TPS)
(11), and the experimental apparatus (13). We then describe the
analysis methods for assessing the impact of managing
heterogenous anatomical motion with the multi-phase
4D approach.

Treatment Planning System and Treatment
Delivery System
Treatment plans were created with the research TPS developed at
GSI Helmholtzzentrum für Schwerionenforschung GmbH (GSI),
called TRiP4D (15). This is an extension of TRiP98 (16, 17),
which takes into account changes in patient anatomy caused by
respiratory motion. Several previously established planning
strategies were used, including conventional- and robust 4D
optimization and conventional- and robust 3D optimization
(these are each explained below). To create a 4D treatment
plan, a 3D sub-plan is created on each of the respiratory
motion phases found in a 4DCT image set. The library of subplans is utilized together as a complete, or composite, treatment
plan. In this study, we used two simple phantoms to represent
the human thorax and a moving tumor. We purposefully selected
simple phantoms to facilitate direct comparisons of calculated
and measured dose distributions. These comparisons were
essential for validating the dosimetric performance in test
scenarios where the target depth or range varied in time. More
speciﬁcally, two types of variations were considered, including
constant range variations (created with a moving, homogenous
wedge), and discrete range variations (created by a moving slab
containing heterogeneities).
4D treatment plans were created for each phantom. First,
4DCT image sets were created by shifting a 4/3p 3 × 3 × 2 cm3
ellipsoid target or a 6 × 6 × 4 cm3 cuboid target contour within a
simulated water box phantom. The targets followed a 20 mm,
Lujan2-type motion trajectory (18) that was lateral to the beam
axis. To explore the impact of the number of motion phases on
delivery quality, we created 4D plans containing 3, 6 and 10
motion phases. Sub-plans were optimized to cover the clinical
target volume (CTV) in each motion phase with a fraction of the
prescription dose, such that the sum of the sub-plan doses results
in the target receiving the prescription dose. For 3D
optimization, 3DCT image sets of the ellipsoid and cuboid
targets were created and used during treatment planning.
Analogous treatment plans were created using conventional
and robust optimization planning techniques. For conventional
optimization, treatment plans were created for CTVs which had
3 mm isotropic margins, while for robust optimization, margins
were calculated from nine uncertainty scenarios, including range
uncertainties and target position shifts, to minimize their
dosimetric impact. Robust optimization was described by Wolf
et al. (19). Robustly and conventionally optimized plan libraries
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monitored in real time with an optical distance laser sensor
(13, 23).
Both setups contained a range modifying phantom. These
included a wedge-shaped piece of PMMA (‘wedge phantom’)
and a rectangular shaped piece of PMMA (‘density phantom’)
with three air cavities (Figure 1). These were used to test
uniform, gradual changes to the thickness proximal to the
target, and discrete gradients from air gaps, respectively. The
wedge phantom was 100 × 70 × 128 mm3, with a lateral slope of
0.3 mm/mm. The density phantom was a 160 × 109.9 × 30 mm3
block of PMMA with 15.8-, 12.0-, and 8.1-mm diameter
cylindrical air gaps. In both cases, the wedge and density
phantoms remained stationary and were placed in front of the
detector and water-equivalent plastic slabs, which were placed on
top of the moving linear stage. The density phantom induced
range changes of 5.5 to 18.4 mm and the wedge phantom
induced a maximum range gradient of 8.8 mm/mm. In
addition to the MP4D deliveries, 3D optimized plans were
delivered to moving targets, without motion mitigation, to
assess the dosimetric impact of motion interplay effects.
Similarly, 3D-optimized plans were delivered to static targets
to determine the reference dosimetric performance of the
treatment delivery system.

within a single delivery, we used a binary range shifter
comprising polyethylene (PE) plastic slabs (21, 22). The
treatment plans contained beam energy codes, that speciﬁed
the needed beam energy for each slice of the treatment plan.
These codes were converted to range shifter settings, where the
range shifter settings speciﬁed the insertion of a combination of
range shifting absorber slabs to modulate the beam range. Each
of the selected binary codes corresponds to a combination of
plastic slabs that allowed for shifting the beam spots
longitudinally by as little as 0.1 mm increments. During beam
delivery, the switching of range shifter settings was synchronized
with the spill cycles of the synchrotron. The range shifter was
further described elsewhere (22).
This motion-synchronized dose delivery system was
previously implemented into the M-DDS and preliminary tests
were reported (13).

Experimental Setup
Plan libraries were delivered to two setups, containing a
heterogenous phantom, and moving slabs and dosimeters
(Figure 1). Treatment deliveries were repeated twice for each
setup: once to irradiate a 2D ionization chamber (IC) array
detector (Octavius 1500XDR; PTW, Freiburg, Germany) and
again to a stack of six radiochromic ﬁlms (EBT3 Gafchromic;
International Specialty Products, Wayne, NJ). The 2D IC array
detector was placed within a 5 mm thick PMMA holder, and 6
ﬁlms, were slotted into the ﬁlms stack, between 10 mm slabs of
PMMA (21). The 2D IC array detector, containing ICs ﬁlled with
air at ambient pressure, was set to integral mode to measure total
delivered dose. Both holders were mounted on top of a
motorized linear stage (M-414.2PD; Physik Instrumente (PI)
GmbH, Karlsruhe, Germany), aligned perpendicularly to the
beamline. Slabs of water equivalent plastic, corresponding to
56.7 mm water-equivalent thickness (WET) were placed in front
of these holders, on the linear stage. The linear stage was
programmed to move with a 20 mm, uni-axial Lujan2-type
respiratory motion-like pattern (18), and the motion was

Data Analysis
The dosimetric quality of deliveries through the multiple range
phantoms was analyzed by reconstructing beam monitoring data
from treatment delivery log ﬁles of the M-DDS. The dose
delivery data log ﬁles were reconstructed on the 4DCT images
containing a simulated water-box phantom. The dose delivery
data log ﬁles and motion monitoring data log ﬁles, from the
motion monitoring system (13), were parsed and reformatted
into the TRiP4D treatment plan format. TRiP4D was then used
to calculate (reconstruct) the delivered dose distributions from
the reformatted ﬁles. The dose distributions were calculated on
the same target volumes as used during treatment planning. We
then compared the reconstructed, planned and measured dose

FIGURE 1 | Setups for testing motion compensation through heterogenous targets. A combination of four setups were used with either the wedge or density
phantom and where measurements were made with either an IC array detector or ﬁlm stack. A top view of the wedge-shaped phantom (left) and slab phantom with
density heterogeneities (right) are shown, placed in front of a periodically moving linear stage. For all setups, the dosimeter was placed behind a set of plastic slabs.
Isocenter is marked with a red circle and the linear stage movement is indicated with a red arrow.
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distributions. The dosimetric quality metrics we selected to assess
motion management included uniformity, conformity, dose
coverage and overdose. Each of these metrics were calculated
from dose volume histogram (DVH) data from planned and
delivered dose reconstructions. Conformity number is
CN =

VT,p VT,p

VT
Vp

delivered with 280 MeV/u carbon ion beams without range
modulation. Each measurement was repeated three times. The
same ﬁeld was delivered to a ﬁlm at 5 mm depth to measure ﬁeld
homogeneity. This QA approach was selected because it is well
established, fast and because beamtime for QA procedures was
severely limited at the time of this study.
We deﬁned reference conditions to facilitate calibrations of
two dosimeters (a 2D IC array detector and radiochromic ﬁlms).
The reference conditions comprise three major elements,
namely, a reference radiation ﬁeld, a reference phantom, and a
reference measurement location. The reference radiation ﬁeld
comprised a 280 MeV/u carbon ion beam without range
modulation and with an incident beam spot size of 6.7 mm
full-width half maximum, delivered to a measurement depth of
5 mm, at isocenter.
We calibrated the 2D IC array detector and ﬁlm to absorbed
dose under reference conditions. The calibrations of these
dosimeters were based on measurements of their responses to
irradiations of known absorbed dose. The known absorbed dose
was determined from dose reconstructions, which were
previously calibrated and are described elsewhere (11). We
simultaneously calibrated the IC array detector and ﬁlms. The
detector was positioned at isocenter, inside of a 31 × 40 × 4 cm3
box-like holder with 5 mm water-equivalent thick walls. A ﬁlm
was taped directly in front of the 2D IC array detector, inside the
holder. A calibration plan was delivered that comprised eight
30 × 30 mm2 square ﬁelds, ranging in ﬂuences from 5 × 104 to 1 ×
107 particles/mm2, corresponding to absorbed doses of 0.1 to 9.9
Gy at 1 cm depth, in the plateau region. The initial beam energy
was 280 MeV/u, and no additional range modulation was
introduced. This interval of absorbed dose values was selected
to encompass the dynamic range anticipated for the clinical
deliveries and to remain within the dynamic range of optical
densities for radiochromic ﬁlms.
We used an established formalism to calibrate the IC array
detector (13, 21, 29). These are brieﬂy reviewed here for the
convenience of the reader. The IC array detector was calibrated
to absorbed dose to water under reference conditions. Measured
absorbed dose is given by

(1)

where VT,p is the portion of the CTV that receives a dose that is
greater than or equal to the prescribed dose, Dp, VT is the CTV,
and Vp is the volume that receives a dose that is greater than or
equal to Dp (24). A CN value of 100% is ideal and, while there is
no threshold for an acceptable CN, we considered > 60% to be
acceptable. Homogeneity (HI), which is a measure of delivery
uniformity, is
HI = D5 − D95

(2)

where D5 and D95 are the percentages of the prescription dose,
Dp = 3 Gy, which are delivered to 5 % and 95 % of the tumor
volume, respectively (25). An HI of 0 % is ideal and < 5 % was
considered acceptable (26). Tumor dose coverage, which is the
percentage volume of the CTV that received at least 95% of the
Dp, is represented by V95. A V95 of 95% was considered clinically
acceptable. Overdose, denoted by V107, is the percentage of the
CTV that receives over 107 % of the prescription dose. Zero
overdose is ideal. The acceptable ranges for these metrics were
selected for the purposes of this study.
Each measured dose distribution was compared to the
corresponding planned dose distribution and reconstructed
dose distribution. The 3D generalized gamma index analysis
(27), was used to quantify the degree of agreement between each
pair of dose distributions. With the generalized gamma index
analysis, we were able to objectively select magnitudes for the
distance to agreement and dose difference criteria for our data
set. This allowed for more accurate characterization of the
dosimetric agreement in the low-dose region. Pass criteria of
3 % dose difference and 3 mm distance to agreement were
applied in all cases. Pass rates of > 90 % were considered
acceptable. The purpose of comparing measured and
reconstructed dose distributions was to validate the accuracy of
the dose reconstruction method. The purpose of comparing
measured and planned dose distributions was to determine the
amount of unintended delivered dose during beam gating and
spill pauses.

DIC = M  C  kQ

where M is the measured response (corrected for leakage,
temperature, and pressure) and C is the calibration coefﬁcient
under reference conditions, kQ corrects for the effects of the
difference between the reference conditions and the nonreference conditions. We conﬁrmed the stability of the
previously determined value of C = 1.2 Gy per unit of
measured response, following methods similar to those
described by Stelljes et al. (30). The effects of non-reference
conditions were negligible and kQ was approximated as unit
value. The absolute absorbed dose values, at the same locations as
the ICs and under reference conditions, were also reconstructed
from delivery log ﬁles, which allowed us to calculate dosimetric
outcomes from the reconstructions.
We used radiochromic ﬁlms to simultaneously measure
relative 2D absorbed dose distributions under reference and

Quality Assurance
We performed limited quality assurance (QA) on the beam
output prior to dosimetry measurements. The QA comprised
relative dosimetry, using the methods described by Luoni et al.
(28). Speciﬁcally, the constancy of the beam output (relative
absorbed dose) was measured with a farmer-type ionization
chamber (PTW 30010 Farmer Chamber; PTW, Freiburg,
Germany), placed at isocenter. The farmer chamber was
inserted into a 30 × 30 × 1 cm3 water-equivalent plastic holder
slab, with a water-equivalent point of measurement at 5 mm
depth. A 5 × 5 cm2 square ﬁeld of 2 Gy absorbed dose was
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non-reference conditions. Films allowed for faster data
acquisition at multiple depths during the limited beamtime
available. They also provided the high spatial resolution needed
to measure dose distributions distal to the wedge and
density phantoms.
We used methods similar to those of Yonai et al. (31) for
calibrating the ﬁlm response to relative absorbed dose, which are
brieﬂy reviewed here for the convenience of the reader. First, the
TPS was used to create a calibration plan under reference
conditions, described above. The calibration plan was delivered
to the radiochromic ﬁlm, in the geometry described above. The
exposed ﬁlms aged for one day, then were digitized
(DosimetryPro Advantage Red; VIDAR Systems Corporation,
Herndon, VA, USA) using a 16-bit sampling and 300 dots per
inch resolution. The net optical density of the scanned ﬁlm was
determined by
ODnet = ODm − ODbkg

RESULTS
Figure 2 reveals that the reconstructed dose distributions agree
well with the corresponding dose distributions obtained from
measurements with ﬁlm. This result conﬁrms the suitability of
the method for reconstructing dose distribution for the main
purpose of this study, which is to assess the quality of dose
distributions delivered by various techniques. We defer
discussion of the results on conﬁrming of the reconstruction
methods until later in this section.

Dosimetric Validation
Relative dosimetry was performed prior to experiments by
delivering a uniform square proﬁle to a farmer-type IC and a
radiochromic ﬁlm. Output constancy was veriﬁed, and beam output
ranged from 2.57 to 2.59 Gy at isocenter. Field homogeneity was
also measured with the homogeneity index, and was 4.8%.
We assessed the dosimetric quality of deliveries through the
wedge and the density phantoms. Measured absorbed dose
distributions were compared to the corresponding dose
distributions from reconstructions and treatment plans.
Figure 3 plots the absorbed dose distributions for these
deliveries, including those with a static target, moving target
without motion compensation (revealing the extent of interplay),
and moving target with the multi-phase 4D approach (revealing
the effectiveness of motion mitigation).
Speciﬁcally, dosimetric quality was assessed with four metrics:
conformity, homogeneity, coverage, and overdose (Figure 4). The
major qualitative ﬁnding from these results is that 10-phase MP4D
deliveries provided the best overall dosimetric quality. The major
qualitative ﬁnding is that 10-phase and 6-phase MP4D deliveries
had acceptable dosimetric quality, while quality metrics for 3phase MP4D were mixed. Figures 2, 3 reveals that the
reconstructed dose distributions agree well with measurements.
Acceptable conformity (CN > 60 %) was obtained in all MP4D
deliveries with 6 and 10 phases. However, at least 10 motion
phases were required to achieve acceptable homogeneity (HI <
5 %) of the absorbed dose in the CTV. Fewer motion phases
produced unacceptably large heterogeneities, due to interplay
effects within each motion phase (so-called “residual motion”).

(4)

where ODm is the measured (scanned) optical density, and ODbkg
is the background optical density scanned in an unirradiated area
on each ﬁlm. The ODnet was determined in the central region of
each square ﬁeld in the calibration ﬁlm. The known absorbed
dose values at the center of each square ﬁeld, Dﬁlm, were ﬁt to
eight measured ODnet values according to
Dfilm = Dfilm,uncorr  kQ,film

(5)

where Dﬁlm,uncorr is the uncorrected, measured absorbed dose
from ﬁlms, and kQ,ﬁlm is a correction factor for changes in the
ﬁlm response due to changes in beam quality at non-reference
conditions, including other depths. The value kQ,ﬁlm corresponds
to a factor that is called relative efﬁciency elsewhere (31, 32). By
deﬁnition, kQ,ﬁlm took a value of 1 at the reference condition used
for the calibration. Under non-reference conditions, the value of
the correction factor kQ,ﬁlm corrected for changes in the ﬁlm
response due to quenching, which depends on beam quality, as
speciﬁed by the beam’s linear energy transfer. Both Dﬁlm,uncorr
and kQ,ﬁlm were calculated using methods modiﬁed from Yonai
et al. (31). The calibration procedure above was performed
separately for each batch of ﬁlm used.

FIGURE 2 | Comparison of ﬁlm measurements (top row) to dose reconstructions (middle row). The top row shows the ﬁlms from a ﬁlm stack for a multi-phase 4D
delivery using 10 motion phases to the wedge phantom with 20 mm uniaxial motion. Films are ordered left to right with increasing depth in the wedge phantom. The
depth increment between ﬁlms is approximately 11 mm water-equivalent thickness. The corresponding dose reconstructions for the same delivery are shown in the
middle row.
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FIGURE 3 | Comparison of 2D ionization chamber array detector measurements to dose reconstructions. The bottom row shows measured absorbed dose values
(values inside of small white squares) overlaid on reconstructed absorbed dose distributions (values outside of the small white squares). The dose distributions are
distal to the density phantom (see Figure 1). Distributions are from four delivery techniques: static target, moving target without motion compensation (interplay), and
moving target with multi-phase 4D motion compensation. Multi-phase 4D deliveries are shown using 3, 6, and 10 motion phases in the treatment plan libraries.

the large range uncertainties in low density material of the
phantom into account. These range effects manifest distal to
the cavities of the density phantom, near the end of range. The
MP4D approach reduced these range defects as, the dose
delivered to these regions were “blurred out” by delivering
multiple sub-plans to the target volumes. Regarding the inverse
interplay effect, the MP4D approach exhibited no dose defects
from this (Figures 6B, D). The inverse interplay effect is a serious
concern that is associated with the beam tracking delivery
approach (15). With beam tracking, the beam spot positions
are modiﬁed from their planned positions to compensate for
detected real-time motion. This can deliver uniform doses to the
target but introduces hotspots and cold spots in the beam path,
proximal to the target in healthy tissue. With the MP4D
approach, there were no hotspots in the proximal healthy
tissue. Instead, the lateral extent of the irradiated healthy tissue
was broadened by the amplitude of the target motion. These
ﬁndings on range defects and inverse interplay further suggest
that MP4D approach can provide high quality deliveries.
Figure 2 reveals that the dose reconstruction methods were
conﬁrmed by measurements. In particular, high gamma-index
pass rates conﬁrmed the accuracy of the treatment planning and
dose reconstructions in this study. Speciﬁcally, we compared
dose distributions from measurements with the IC detector array
to those from the corresponding log ﬁle reconstructions
(Figure 7C) and treatment plans (Figure 7B) obtained with
moving targets. Average pass rates increased with the number of
motion phases, due to the decreasing residual motion within
each motion phase. In all cases, reconstructed dose distributions
agreed well with measured dose distributions (Figure 7C), with
pass rates > 90 %, conﬁrming the validity of the dose
reconstruction strategy. Gamma index analysis pass rates were

The average HI value for all of the 10-phase MP4D deliveries (both
phantom types and CTV shapes) was 8 %, approaching the criteria
of < 5 %, which was achieved for static deliveries and is considered
acceptable for other deliveries. Target coverage was 100 % for 10phase MP4D deliveries and was > 98 % for 6-phase MP4D
deliveries, also approaching the ideal results of 100%, which
were obtained from deliveries to a static target. These ﬁndings
on coverage and heterogeneity are qualitatively supported by dose
distributions plotted in Figure 3, which shows that the MP4D
approach produces similar results for the static and 10-phase
MP4D deliveries. It was expected that the deliveries using 10
motion phases would have superior results, since the residual
motion was less than that with 6 or 3 motion phases. The
increasing homogeneity is also seen in Figure 5, where the
range of average measured absorbed dose values narrow with
increasing number of motion phases. Here, the average absorbed
dose was within ± 1.5 % of the prescription dose for MP4D
deliveries. Finally, the 10-phase MP4D approach produced
hotspots in the CTV that were < 103% of the prescribed
absorbed dose. Together, these ﬁndings suggest that the 10phase MP4D approach provides good dosimetric quality that
closely approaches the quality that was achieved for statictarget deliveries.

Effectiveness of Multi-Phase 4D Delivery
The results of MP4D deliveries also yielded important ﬁndings
regarding over- and undershoot of the beam range and regarding
the inverse interplay effect. Regarding range effects, absorbed
dose distributions from treatment plans and dose reconstructions
are shown in Figure 6 (SlicerRT, Kingston CA), which illustrates
that static robust optimization created dose distributions with
range over- and undershoots. These are a consequence of taking
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FIGURE 4 | (A) Dose coverage (V95), (B) conformity (CN), (C) overdose (V107), and (D) homogeneity (HI) for static deliveries to stationary targets (static), static
deliveries to moving targets (interplay), and 3-phase, 6-phase and 10-phase multi-phase 4D deliveries to cube and ellipsoid target volumes through the wedge and
density phantom.

lower for comparisons between planned and measured dose
distributions and only static deliveries and 10-phase MP4D
deliveries had pass rates > 90 %.
Similarly, we compared all dose distributions from measurements
to reconstructions of static deliveries (Figure 7A). This comparison
provided important contextual information on the magnitude
of dose degradations that were caused by target motion occurring
within a motion phase and without motion compensation.
Pass rates were < 90 % for comparisons between static
reconstructions and 3 phase MP4D measurements and were
< 60 % for comparisons between static reconstructions and
interplay deliveries. For planning studies, 10 or more motion
phases should be selected.
The total delivery time was calculated from treatment log
ﬁles. Average total delivery time for static ellipsoid deliveries
was 7.4 min. The relative increase in delivery time for 3-phase,
6-phase and 10-phase MP4D deliveries, compared to static
deliveries, was 7%, 17%, and 21%, respectively. This suggests
that the MP4D method provides motion-mitigated deliveries
with increases to delivery time that would be well-tolerated
by most radiotherapy patients and compatible to existing
patient caseloads.

heterogenous phantoms. Speciﬁcally, we measured dosimetric
quality of absorbed dose distributions from plan libraries
delivered through two phantoms. The major ﬁndings of this
study are that the multi-phase 4D (MP4D) dose delivery
approach has acceptable dosimetric quality without
introducing inverse interplay effects.
The implication of this study is that MP4D delivery offers a
promising new alternative approach to motion mitigation that
provides good dosimetric quality with moderate technical
complexity. The magnitude of technical complexity is an
important characteristic because it can be a barrier on the path
of translation of new technologies to clinical practice. One such
technology, ion beam tracking, entails rapidly modifying
planned beam spot positions to the real-time detected target
motion (12, 33). Consequently, the dose distributions delivered
to a patient cannot be fully conﬁrmed by pre-treatment quality
assurance testing. One type of beam tracking, called 4Doptimized tracking, that pre-computes tracking vectors to take
anatomical motion from 4DCTs into account during planning,
still exhibited inverse interplay effects and other dose
degradations (10). The process of adjusting planned beam spot
positions with tracking vectors results in cold- and hotspots in
the proximal normal tissues. Our results suggest that, in the
absence of respiratory-motion-related uncertainties (baseline
drifts and changes to the tumor trajectory), clinically
acceptable projected therapeutic outcomes could be achieved
with the MP4D approach without inducing signiﬁcant hotspots

DISCUSSION
In this study, we validated the dosimetric performance of a novel
multi-phase 4D treatment approach with deliveries to
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B

FIGURE 5 | (A) Average measured absorbed dose versus delivery technique evaluated using the density and wedge phantoms. The dashed grey lines delineate the
± 5 % tolerance interval centered about the prescription absorbed dose of 3 Gy and the bars indicate the spread measured dose values from each ionization
chamber (IC) of the 2D IC array detector in the clinical target volume (CTV) (B) Homogeneity (HI) and coverage (V95) for measured versus reconstructed absorbed
dose distributions in the target volume. Dosimetric quality was calculated in a single iso-energy slice within the CTV and in the entire CTV for each delivery. All
delivery techniques for both phantom types and for both VOIs are plotted. Data points that fall on the line indicate full agreement of measured and reconstructed HI
and V95 values.

The 3D tracking method was reported by Saito et al. (33), and
compensated for translational target motion (only), but beam
spot delivery accuracy was still within 5 mm in the lateral and
longitudinal directions. Importantly, this work revealed several
complications with potentially important clinical implications
for certain situations. First, the so-called “inverse interplay” effect
was observed, due to differences in motions of the target and the
tissue of the entrance channel (35). Second, complex motion,
such as tumor rotations or deformations could not be fully
compensated for (36). Finally, for tissues with large
heterogeneities, no solution was found to compensate for
motion-induced range changes. 4D-optimized tracking (12), or
online adaptive tracking (37) partially solved the latter problem.
However, that 4D tracking implementation encountered several
obstacles, including limitations on the available hardware speed
and memory, and difﬁculties with synchronizing the system
timing. These issues rendered the system obsolete; it was
dismantled and replaced with the motion-synchronized dose
delivery system described here and elsewhere (13).
In consideration of the above, the MP4D delivery strategy is
generally less complex, and allows for integrating a variety of
treatment planning strategies, such as 4D optimization (38). It
also accommodates the pre-treatment quality assurance methods
similar to those currently used clinically (29). Our ﬁndings on
dosimetric quality are comparable to those of the system at NIRS.

in normal tissues (due to inverse interplay effects) and the target
volume (due to interplay effects). This study provides new
evidence that, when considered with other recent studies (13,
29), suggest it may be feasible to translate the MP4D approach to
clinical practice for both carbon ion and proton beam
treatments. It must be emphasized that the MP4D approach is
still in the early stages of preclinical development and testing;
further work is needed to understand how dosimetric quality is
impacted by irregular motion (e.g., baseline drifts and changes to
target trajectories caused by coughs and sneezes). Furthermore,
additional research is needed to implement and evaluate MP4D
deliveries with real-time corrective tracking and to compare the
MP4D approach to the 4D-optimized tracking approach.
This work is broadly coherent with previous literature on
motion mitigation approaches for proton and ion therapies. Our
ﬁndings extend previous preliminary studies that suggested
feasibility of a novel dose delivery system (M-DDS) with
integrated motion-synchronization strategies (13, 29). The
MP4D delivery approach poses a straightforward solution to
solve the limitations of 3D tracking and 4D-optimized tracking.
Previous research at GSI focused on 3D tracking, which required
utilizing a fast wedge system to modulate beam spot delivery
depth and compensate for motion-induced target depth changes
in real-time, during treatment delivery (33, 34). Experiments
conﬁrmed the range compensation capabilities of this system.
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FIGURE 6 | Dose distributions in ellipsoid targets (white ovals) for (A) static and (B) 10-phase multi-phase dose deliveries through the wedge phantom and for
(C) static and (D) 10-phase multi-phase 4D deliveries through the density phantom. Plans were robustly optimized and deliveries were reconstructed from beam
delivery log ﬁles and motion monitoring log ﬁles.

techniques within ion therapy centers (26, 41). Further, the
range changes were measured by delivering beams to simple
phantoms rather than anthropomorphic phantoms (42–44),
eliminating additional variables, such as range uncertainties
associated with variations in tissue density, irregular breathing
patterns, and generally more complex range changes that are
found in a human anatomy. As a result, the delivery quality more
directly reﬂects the capabilities of the MP4D deliver approach.
Nevertheless, geometries that are more complex could further
conﬁrm that our motion-synchronized dose delivery strategy can
compensate for range changes and represent scenarios that are
closer to clinical conditions. Further, in later stages, pre-clinical
tests will be performed with anthropomorphic phantoms to
characterize the full capabilities of the M-DDS.
Our study had several limitations. At the time of these
experiments at GSI, our beam gating system (based on
radiofrequency knockout extraction) could not yet fully gate the
beam (21), and the accelerator system could not yet provide
beams of multiple energies in any one delivery. We discuss both
of these limitations in detail here. The inability to completely gate
the beam results in an insigniﬁcant but observable amount of
undesired radiation that only slightly degraded the dose
distributions. Speciﬁcally, a trend was apparent (Figure 7) that,
as the number of motion phases increased, the average absorbed
dose in the CTV increased as well. The increase was under 0.4%
undesired, additional dose. To overcome the limitation of having
only single energies available, a passive range shifter system was
utilized to modulated beam energy and range. Due to the

At NIRS, phase-controlled rescanning is used to deliver a full set
of rescans during each gating window (39). X-ray ﬂuoroscopy
detects when the tumor is within a pre-deﬁned gating window,
resulting in accurate treatment to the tumor volume. Typical
results for phase-controlled rescanning were a D95 of over 95 %.
Further, clinical outcome data revealed 2-year survival rates were
as high as 82 % for stage 3 lung cancers treated with passive ion
beams (40). This method relies on the fast-scanning magnets of
the HIMAC accelerator at NIRS, and slower beam deliveries may
not be able to achieve the same results. In contrast, our approach
allows for continuously adapting the delivery sequence to
detected motion, with minimal delivery pauses (a maximum
21% observed increase to total delivery time with regular
motion), and with minimal residual motion during active
beam delivery. For these reasons, it appears that the MP4D
approach may ﬁnd broader applicability than is possible with
other approaches.
Our study has several strengths. First, we performed all of our
measurements with a modular and portable dose delivery system
(13), with integrated solutions for motion-synchronized dose
delivery. This is potentially broadly applicable and the M-DDS
has already been demonstrated at multiple centers, including
CNAO and GSI. Additionally, as the motion mitigation portion
of the M-DDS is an optional module, the M-DDS requires no
modiﬁcations to run either with or without the motion
mitigation module. This allows for implementing the M-DDS
in a stepwise manner into existing facilities. We also selected
methods for assessing dosimetric quality that are standard
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FIGURE 7 | Gamma index analysis pass rates versus beam delivery technique. The pass rates indicate good agreement between measured absorbed dose
distributions and (A) reconstructed absorbed dose distributions for the static delivery, (B) planned absorbed dose distributions and (C) reconstructed absorbed dose
distributions. Comparisons were made for static deliveries to stationary targets (static), static deliveries to moving targets (interplay), and multi-phase deliveries to
moving targets with 3 phases, 6 phases, and 10 phases of motion compensation. Pass rates showed only a weak dependence on phantom type (wedge or density
types) and target shape (cube or ellipsoid types).

The results presented in this work are part of an ongoing
effort to develop motion-synchronized dose delivery strategies at
GSI. The motion-synchronized dose delivery system was
previously assessed for safety (29), and the strategy has been
validated against other approaches, including ITV-based
deliveries with rescanning (45). In the future, dose degradation
due to irregular motion and differences between motion during
imaging and during delivery will be quantiﬁed, and corrective
motion tracking will be implemented to correct for irregular
target motion. The long-term goal is to translate the multi-phase
4D delivery approach and motion-synchronized dose delivery
system into clinical use at CNAO.

additional material and air gaps between the range shifter plates,
the beam spot size was strongly dependent on the amount of
range shifter material (29). This was not a serious limitation, as
the range compensation capabilities could still be demonstrated,
and the TRiP4D TPS was updated to take the correct spot sizes
into account in the dose calculation algorithm. In the next stage,
the experiments reported here will be reproduced at CNAO,
where the gating system is tuned for therapy and beam energies of
120 – 400 MeV/u are available for carbon ions (20). Another
limitation of our study is that we have not tested the MP4D
delivery strategy under more complex respiratory scenarios,
including baseline drifts, changes to breathing amplitude and
changes to breathing speed, as well as more extreme respiratory
irregularities, including coughing. Some of these irregular motion
scenarios could result in cold and hotspots in the target volume
and dose to surrounding tissue. These capabilities will be
implemented in later stages, along with improved beam gating,
which will be used for handling unforeseen motion, including
coughing. Finally, we did not compare the MP4D delivery
strategy to other motion handling methods currently used in
clinics [including the gating methods, and ITV-based deliveries
with rescanning (45)] or study the results of combining motion
mitigation strategies. These strategies are studied in detail
elsewhere (45, 46), and delivery degradations in the complete
absence of motion mitigation are shown in this study.
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CONCLUSIONS
We validated the dosimetric performance of multi-phase 4D
treatment delivery with scanned ion beams in the presence of
multiple beam ranges. The results of this work demonstrate that
it is possible to deliver motion compensated dose distributions in
the presence of anatomical heterogeneities. Notably, the
dosimetric performance was achieved without high
technological demands or specialized equipment for mitigating
target motion.
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